FDA Nicotine Pouch Fast-Track Stalls: Why Millions of Smokers Are Still Waiting

The FDA promised speed. It delivered gridlock. A pilot programme designed to fast-track nicotine pouch approvals in the United States has hit a wall, leaving the biggest brands in the industry stuck in regulatory limbo. According to a Reuters exclusive published on April 1, 2026, agency scientists are hesitating to clear popular products over concerns about youth use and new addiction, even as nicotine pouches continue to outsell every other alternative nicotine product on the market.

If you use ZYN, Velo, or any pouch brand that is not Altria's on! PLUS, this story affects you directly. Here is what happened, why it matters, and where things go from here.

What Is the FDA Nicotine Pouch Fast-Track Programme?

In September 2025, the FDA launched a pilot programme to speed up its review of nicotine pouch applications. The agency had been sitting on a backlog of premarket tobacco product applications (PMTAs) for years. Some brands had been waiting since 2020 for a simple yes or no.

The idea behind the pilot was straightforward. Nicotine pouches are tobacco-free, spit-free, and smoke-free. They pose fewer health risks than cigarettes. The FDA acknowledged this publicly. So the agency created a dedicated lane to move pouch applications through faster than the standard review process, which can take three to five years.

Decisions were expected by the end of 2025. That deadline came and went.

Only One Brand Made It Through

Out of five pouch brands in the pilot, exactly one received authorization. In December 2025, the FDA cleared six on! PLUS products from Altria for legal sale. That was it.

Applications from four other brands remain stuck. Philip Morris International's ZYN (the market leader by a wide margin), British American Tobacco's Velo, and two brands from Turning Point Brands are all still waiting. The FDA has not given a timeline for when those decisions will come.

To put the scale of this in perspective: PMI sold 794 million cans of ZYN in the US in 2025. That is more than double what it sold in 2023. The product is already on shelves in gas stations and convenience stores across the country. Millions of Americans use it daily. And the FDA still has not formally authorized the current versions for sale.

Why the FDA Is Dragging Its Feet on Nicotine Pouches

Three sources familiar with the FDA's internal review process told Reuters that agency scientists have specific concerns holding up the remaining applications.

The first concern is youth use. The FDA runs an annual survey tracking nicotine product use among middle and high school students. While pouch use among these age groups remains low, it has ticked upward in recent years. Reviewers want to weigh whether authorizing more brands could accelerate that trend.

The second concern is new adult users. Some FDA scientists worry that pouches are attracting adults who never smoked cigarettes in the first place, creating new nicotine dependency rather than replacing an existing one. One source told Reuters the evidence supporting fast-track authorization was "not as clear-cut as expected."

A third source described the remaining applications as being "in a holding pattern" with "a lot of concerns around risks to youth and children."

The Problem With This Logic

Here is where things get frustrating for anyone who actually follows the science on harm reduction.

The FDA itself has stated that pouches are generally less harmful than cigarettes. When smokers switch completely, scientific data shows they can lower their health risks. The agency said this in a statement to Reuters for the very article reporting the delays.

So the FDA is simultaneously saying "these products are less harmful" and "we are not sure we should let people buy them." That is a contradiction that costs lives.

Every day a smoker does not switch to a pouch because their preferred brand is not available or is not marketed as a reduced-risk option, that is a day they keep inhaling combustible tobacco. The US still has roughly 28 million adult smokers. The American Cancer Society estimates that smoking kills about 480,000 Americans every year. Those numbers do not pause while the FDA deliberates.

Sweden offers a useful comparison. The country has the lowest smoking rate in Europe at under 5%, largely because of widespread adoption of snus and nicotine pouches. Swedish men have the lowest rates of lung cancer and oral cancer in Europe. The products work. The data is there.

Stock Markets Reacted Immediately

Wall Street did not wait for the FDA to make up its mind. When Reuters broke the story on April 1, PMI shares dropped more than 7% before recovering slightly to close 4.8% lower. BAT fell 1.5%. Turning Point Brands plunged over 17%.

Jefferies analyst Andrei Andon-Ionita pointed out that pouch valuations had become a significant part of these companies' stock prices. Investors had assumed regulatory approval would be relatively smooth because, well, the science supports it. The delay caught them off guard.

Andon-Ionita also noted that the situation is worse for PMI specifically. ZYN has been losing market share to newer competitors while its updated product versions sit in the FDA's review queue. The company cannot launch improved formulations without authorization, so it is stuck selling older versions while rivals chip away at its dominance.

The $22 Billion Market Nobody Can Legally Sell Into

The US is the world's largest market for smoking alternatives, worth an estimated $22 billion. Nicotine pouches are the fastest-growing segment within that market. And yet, a huge portion of the products being sold have never received formal FDA authorization.

This creates an absurd situation. Brands that played by the rules and submitted PMTAs years ago are still waiting for approval. Meanwhile, unauthorized products flood convenience store shelves with zero regulatory oversight. The FDA's own pilot programme was supposed to fix this imbalance. Instead, the bottleneck has gotten worse.

Both PMI and BAT released statements saying the pilot programme could help support public health and restore fair competition. That is corporate-speak for "please just make a decision already."

What the Anti-Tobacco Lobby Gets Wrong

Groups like the Campaign for Tobacco-Free Kids have been vocal about their opposition to nicotine pouches. Their argument boils down to a concern that more liberal marketing and growing popularity could lead to higher youth use in the future.

That concern deserves a reality check. The FDA's own survey data shows youth pouch use remains low. Compare that to the vaping crisis of 2019-2020, where teen use of e-cigarettes skyrocketed while the FDA looked the other way for years. Pouches have shown nothing close to that trajectory.

There is also the inconvenient truth that nicotine itself, while addictive, is not what kills smokers. It is the combustion, the tar, the thousands of chemicals in cigarette smoke. A pouch delivers nicotine without any of that. Blocking access to pouches in the name of protecting youth while cigarettes remain freely available in every shop is not a coherent public health strategy.

What Happens Next for ZYN and Velo?

The FDA told Reuters that applications in the pilot are "on track for faster decisions than most others." That is technically true but deeply unhelpful. The standard review timeline is measured in years. Being faster than glacial is not the win the agency thinks it is.

Several things could break the logjam. The FDA's advisory committee already met in January 2026 to discuss ZYN's modified risk tobacco product (MRTP) application. If the FDA grants ZYN "reduced risk" marketing authorization, it would signal strong institutional support for the product category and could accelerate PMTA decisions.

Political pressure is also mounting. Tobacco lobbyists and the White House have pushed the FDA to authorize more brands. Congress recently directed at least $200 million in tobacco user-fee funds toward enforcement against unauthorized products. That money only makes sense if there are authorized products to replace the unauthorized ones.

PMI is also building a new manufacturing facility in Colorado set to begin production in 2026. The company is clearly betting on eventual approval. It would not invest hundreds of millions in US manufacturing capacity if it expected the FDA to shut the door.

What This Means for Nicotine Pouch Users

If you are currently using ZYN, Velo, or another pouch brand in the US, nothing changes for you immediately. These products are still available for purchase. The FDA has not ordered any removals or bans.

What the delay does affect is product innovation. New flavors, improved formulations, and updated nicotine strengths cannot hit the market until the FDA clears them. ZYN recently launched five new flavors in Europe, including Black Currant Ice and Black Cherry, but US consumers may have to wait months or years to see similar releases domestically.

For smokers considering a switch, the delay also means reduced-risk marketing claims remain off limits for now. ZYN cannot tell you on its packaging that it is safer than cigarettes until the FDA approves its MRTP application. So the very information that might convince a smoker to switch stays locked behind a regulatory gate.

The Bigger Picture: Regulation vs. Harm Reduction

This story is about more than one FDA pilot programme. It is about whether regulators can move fast enough to keep up with a market that has already decided what it wants.

American consumers bought nearly 800 million cans of ZYN alone last year. They are choosing pouches over cigarettes, over vapes, over chewing tobacco. The market has spoken. The science supports their choice. And the FDA is still figuring out the paperwork.

Other countries are moving faster. The UK treats nicotine pouches as consumer products with light-touch regulation. Sweden's decades-long embrace of oral nicotine has produced the best smoking-related health outcomes in Europe. Even the EU, despite some member states like France pursuing bans, is grappling with how to regulate pouches as a distinct, lower-risk category.

The US has a choice. It can lead on tobacco harm reduction, or it can keep putting speed bumps in front of products that are already saving lives. Right now, it is choosing speed bumps.

Frequently Asked Questions

Is ZYN FDA approved?

Yes and no. The FDA authorized 20 ZYN nicotine pouch products for sale in January 2025 after extensive scientific review. But newer versions of ZYN that PMI submitted through the fast-track pilot programme have not yet been cleared. The original authorized products remain legally on sale.

What is the FDA nicotine pouch fast-track programme?

It is a pilot programme the FDA launched in September 2025 to speed up review of nicotine pouch premarket tobacco product applications (PMTAs). The goal was to deliver faster decisions while maintaining scientific standards. So far, only six on! PLUS products from Altria have been cleared through the pilot.

Why is the FDA delaying nicotine pouch approvals?

According to Reuters sources, FDA reviewers have concerns about potential risks to youth and non-tobacco users. Some scientists worry that authorizing more pouch brands could drive new nicotine addiction rather than just helping existing smokers switch. The agency says decisions are based on science and law.

Are nicotine pouches safer than cigarettes?

The FDA itself has stated that nicotine pouches are generally less harmful than cigarettes. When smokers switch completely, scientific data indicates they can lower health risks. Pouches contain no tobacco leaf, produce no smoke, and eliminate exposure to tar and combustion byproducts.

What happened to PMI and BAT stock after the FDA news?

PMI shares fell more than 7% on the day Reuters reported the delays, recovering slightly to close 4.8% lower. BAT dropped 1.5%. Turning Point Brands, which has two pouch brands in the pilot, plunged over 17%. Analysts noted that pouch valuations had become a big part of these companies' stock prices.

How many cans of ZYN were sold in the US in 2025?

Philip Morris International sold 794 million cans of ZYN in the US in 2025, more than double its 2023 sales figures. ZYN remains the market leader in the nicotine pouch category by a significant margin.

Will the FDA eventually approve ZYN's fast-track application?

The FDA has not given a specific timeline. The agency told Reuters that pilot applications are "on track for faster decisions than most others." PMI's investment in a new Colorado manufacturing facility suggests the company expects eventual approval. The modified risk tobacco product (MRTP) application review, which had an advisory committee meeting in January 2026, could also influence the timeline.

What new ZYN flavors are available in 2026?

ZYN launched five new flavors for European markets in 2026: Black Currant Ice Super Strong (13.5mg), Black Cherry Strong (9mg), Menthol Ice Super Strong (13.5mg), Red Fruits Strong (9mg), and Gentle Mint Moist Low (3mg). These are not yet available in the US due to the pending FDA authorization.

Can I still buy nicotine pouches in the US?

Yes. Nicotine pouches including ZYN, Velo, on!, and others remain available for purchase across the US. The FDA has not ordered any product removals. The current delay affects new product versions and updated formulations, not existing products already on shelves.

How does the US compare to other countries on nicotine pouch regulation?

The US has one of the most complex regulatory frameworks for nicotine pouches. The UK treats them as consumer products with minimal regulation. Sweden has embraced oral nicotine for decades and has Europe's lowest smoking rate. France banned pouches entirely from April 2026. Austria now requires sales through licensed tobacco shops only.

What is a modified risk tobacco product (MRTP)?

An MRTP is a tobacco product that the FDA has authorized to be marketed with claims about reduced health risks. ZYN has applied for MRTP status, which would allow it to tell consumers that the product poses lower risks than cigarettes. The FDA's advisory committee reviewed the application in January 2026, and the agency indicated the scientific claim appears accurate.

Why does the FDA fast-track delay matter for public health?

Roughly 28 million Americans still smoke cigarettes. Smoking kills about 480,000 Americans annually. When the FDA delays authorization of less harmful alternatives, it potentially keeps smokers on cigarettes longer. Faster access to authorized, lower-risk products could accelerate the decline in smoking rates and save lives.

Sources and Further Reading